Decreasing trend of blood lipid profile in type 2 diabetes: Not a promising change in HDL-C, a serial cross-sectional study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
11
2022
accepted:
03
10
2023
medline:
27
10
2023
pubmed:
25
10
2023
entrez:
25
10
2023
Statut:
epublish
Résumé
The prevalence of dyslipidemia in patients with type 2 diabetes (T2D) has been reported to be relatively high. The current study aimed to investigate the trend of serum lipid levels and the prevalence of dyslipidemia in patients with T2D. Data were extracted from a cohort of patients with T2D who had regular follow-ups every year for three years. TG, TC, LDL-C, HDL-C, and non-HDL-C were analyzed. The atherogenic index of plasma (AIP) was calculated using log (TG/HDL-C). A total of 747 patients with T2D were included in this study, consisting of 469 (62.8%) women and 278 (37.2%) men. There was a significant downward trend in mean TG, TC, LDL-C, non-HDL-C, and AIP levels. The trend of mean HDL-C levels showed no significant change. The prevalence of high TG, high TC, high LDL-C, and high non-HDL-C significantly decreased from the first to the last visit. There was no significant change in the trend of prevalence of low HDL-C. The prevalence of high AIP significantly decreased in women and showed no significant changes in men. A decreasing trend was observed in the mean levels and prevalence of TG, TC, LDL-C, non-HDL-C, and AIP. HDL-C did not change significantly. The success rate in achieving a complete normal lipid profile during follow-up years was not promising and continues to be challenging.
Sections du résumé
BACKGROUND
The prevalence of dyslipidemia in patients with type 2 diabetes (T2D) has been reported to be relatively high. The current study aimed to investigate the trend of serum lipid levels and the prevalence of dyslipidemia in patients with T2D.
METHODS
Data were extracted from a cohort of patients with T2D who had regular follow-ups every year for three years. TG, TC, LDL-C, HDL-C, and non-HDL-C were analyzed. The atherogenic index of plasma (AIP) was calculated using log (TG/HDL-C).
RESULTS
A total of 747 patients with T2D were included in this study, consisting of 469 (62.8%) women and 278 (37.2%) men. There was a significant downward trend in mean TG, TC, LDL-C, non-HDL-C, and AIP levels. The trend of mean HDL-C levels showed no significant change. The prevalence of high TG, high TC, high LDL-C, and high non-HDL-C significantly decreased from the first to the last visit. There was no significant change in the trend of prevalence of low HDL-C. The prevalence of high AIP significantly decreased in women and showed no significant changes in men.
CONCLUSIONS
A decreasing trend was observed in the mean levels and prevalence of TG, TC, LDL-C, non-HDL-C, and AIP. HDL-C did not change significantly. The success rate in achieving a complete normal lipid profile during follow-up years was not promising and continues to be challenging.
Identifiants
pubmed: 37878656
doi: 10.1371/journal.pone.0293410
pii: PONE-D-22-32065
pmc: PMC10599547
doi:
Substances chimiques
Cholesterol, LDL
0
Lipids
0
Triglycerides
0
Cholesterol, HDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0293410Informations de copyright
Copyright: © 2023 Yadegar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
BMC Public Health. 2022 Mar 28;22(1):596
pubmed: 35346132
Cardiol Clin. 2015 May;33(2):233-43
pubmed: 25939296
Hormones (Athens). 2018 Mar;17(1):61-67
pubmed: 29858856
Obesity (Silver Spring). 2019 Feb;27(2):309-314
pubmed: 30677260
J Chronic Dis. 1986;39(9):699-707
pubmed: 3734024
Ophthalmol Retina. 2018 Jan;2(1):38-45
pubmed: 31047300
Diabetes Metab Syndr Obes. 2021 Oct 07;14:4189-4197
pubmed: 34675571
Sci Rep. 2020 Jul 16;10(1):11724
pubmed: 32678170
Lipids Health Dis. 2017 Oct 30;16(1):207
pubmed: 29084567
J Clin Invest. 2007 Mar;117(3):746-56
pubmed: 17332893
Transl Oncol. 2021 Jun;14(6):101043
pubmed: 33751965
Int J Mol Med. 2000 Feb;5(2):201-5
pubmed: 10639602
Int J Endocrinol. 2018 Apr 26;2018:9317987
pubmed: 29853887
Lipids Health Dis. 2022 Aug 25;21(1):77
pubmed: 36002855
Diabetes Metab Syndr. 2019 May - Jun;13(3):1733-1737
pubmed: 31235086
Diabetes Metab Syndr Obes. 2020 May 14;13:1633-1642
pubmed: 32523363
Drugs. 2013 Mar;73(4):327-39
pubmed: 23479408
QJM. 2009 Sep;102(9):657-67
pubmed: 19498039
Nat Sci Sleep. 2020 Jun 08;12:325-332
pubmed: 32607032
Diabetes Obes Metab. 2021 May;23(5):1150-1161
pubmed: 33496366
Rev Diabet Stud. 2013 Summer-Fall;10(2-3):121-32
pubmed: 24380088
Biochem Pharmacol. 2022 Feb;196:114654
pubmed: 34129857
Curr Med Res Opin. 2005 Dec;21(12):1927-34
pubmed: 16368042
Br Med Bull. 2013;108:5-24
pubmed: 24103335
Diabetes Ther. 2016 Jun;7(2):203-19
pubmed: 27056202
Food Sci Nutr. 2022 Mar 10;10(4):1003-1020
pubmed: 35432965
Int J Endocrinol. 2015;2015:818075
pubmed: 26089896
Food Sci Nutr. 2023 Jun 30;11(10):5967-5977
pubmed: 37823170
Phytother Res. 2022 Jun;36(6):2352-2374
pubmed: 35583807
Am J Cardiol. 1995 Mar 1;75(7):455-9
pubmed: 7863988
JAMA. 2016 Sep 27;316(12):1289-97
pubmed: 27673306
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
Diabetes Care. 2016 Nov;39(11):2065-2079
pubmed: 27926890
J Clin Lipidol. 2020 Jul - Aug;14(4):425-430
pubmed: 32467016
BMC Public Health. 2020 Feb 3;20(1):166
pubmed: 32013917
Acta Med Iran. 2013;51(9):642-51
pubmed: 24338197
J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350
pubmed: 30423393
J Public Health (Oxf). 2020 Nov 23;42(4):e468-e476
pubmed: 31728508
Cardiovasc Drugs Ther. 2008 Aug;22(4):321-38
pubmed: 18553127
Oncology. 2005;68(4-6):371-4
pubmed: 16020965
PLoS One. 2018 Mar 6;13(3):e0193756
pubmed: 29509776
Curr Cardiol Rev. 2009 Aug;5(3):216-22
pubmed: 20676280
J Am Coll Cardiol. 2015 Oct 13;66(15):1643-53
pubmed: 26449133
Int J Clin Pract. 2007 Nov;61(11):1905-13
pubmed: 17655681
Nutr Metab Cardiovasc Dis. 2023 Jul;33(7):1367-1376
pubmed: 37156669
J Am Coll Cardiol. 2013 Aug 20;62(8):697-703
pubmed: 23810877
Diabetes Care. 2013 Aug;36(8):2271-9
pubmed: 23418368
World J Diabetes. 2016 May 25;7(10):209-29
pubmed: 27226816
J Clin Lipidol. 2018 Nov - Dec;12(6):1471-1481.e4
pubmed: 30195823
Vnitr Lek. 2006 Jan;52(1):64-71
pubmed: 16526201